drugset
drugset / Trial / NCT04945772

Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

NCT04945772 ↗

Phase 2 Completed 27 enrolled Nanoscope Therapeutics Inc.
RandomizedSequentialTriple-blindTreatment

Summary

The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).

Timeline

Start
2021-07-13
Primary completion
2023-02-27
Completion
2024-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject MCO-010 Gene therapy (AAV / viral vector) 9e+10 vg Intravitreal
Subject MCO-010 Gene therapy (AAV / viral vector) 1.2e+11 vg Intravitreal

Indications

hereditary neuro-ophthalmological disease retinitis retinitis pigmentosa